Simple Summary
Managing pain after surgery is important for the welfare and recovery of dogs. This study investigated whether gabapentin could provide additional benefits when given alongside anaesthetic and pain-relief treatments to dogs undergoing orthopaedic surgery. Dogs receiving gabapentin had lower overall pain scores, although differences were not consistently observed at individual assessment timepoints. They also did not require less additional pain medication than dogs receiving placebo. Gabapentin was associated with increased sedation after surgery, which may have influenced how pain-related behavioural were expressed and assessed. Differences in anaesthetic requirements were also observed for selected outcomes and timepoints, but these findings need further investigation. Overall, increased sedation after surgery was the most consistent treatment-related finding. The results do not establish a clear additional benefit of gabapentin for pain relief. Further clinical studies are needed to determine whether gabapentin provides a clinically meaningful improvement in pain management for dogs undergoing surgery.
Abstract
Perioperative gabapentin is increasingly used as an adjunct to multimodal analgesia in dogs, although its effects during orthopaedic surgery remain uncertain. This prospective, randomized, placebo-controlled two-period crossover study evaluated perioperative oral gabapentin in 11 dogs undergoing bilateral ulnar osteotomy. Dogs received gabapentin or placebo within a standardized multimodal anaesthetic and analgesic protocol. Anaesthetic and analgesic requirements, pain and sedation scores, rescue analgesia, cardiopulmonary variables, adverse effects, and recovery quality were evaluated. Gabapentin was associated with lower postoperative CMPS-SF scores (median treatment difference, −0.75 points; 95% CI, −1.07 to −0.43; p < 0.001), although unadjusted paired comparisons showed no significant differences at individual timepoints. This association persisted, although attenuated, after adjustment for concurrent sedation and other covariates (difference, −0.51 points; 95% CI, −0.98 to −0.047; p = 0.031). Rescue analgesia requirements did not differ significantly between treatments. Gabapentin increased sedation scores (median treatment effect, +1.19 points; 95% CI, 0.66–1.73; p < 0.001) and reduced propofol induction requirements (mean reduction, 0.59 mg/kg; 95% CI, 0.26–0.92; p < 0.001). Lower ETISO was observed at one late intraoperative timepoint. No consistent pattern of clinically important haemodynamic effects was evident. Increased perioperative sedation was the most consistent treatment-related finding. The clinical significance of the pain-score differences remains uncertain, particularly given the potential influence of sedation on behavioural pain assessment. These preliminary findings do not establish a clinically meaningful analgesic benefit and require confirmation in prospective clinical studies.